After conducting a thorough search, there is no clear evidence or documented cases of the drug Lurbinectedin directly causing fetal abnormalities. Lurbinectedin is an anticancer drug that is used to treat small cell lung cancer, and it works by inhibiting the replication and transcription of DNA [1].

However, it is important to note that Lurbinectedin is a relatively new drug, and its effects on fetal development have not been extensively studied. Therefore, it is generally recommended that women who are pregnant or planning to become pregnant avoid taking this drug [2].

Furthermore, Lurbinectedin is classified as a Category D drug by the FDA, which means that there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks [3].

In summary, while there are no documented cases of Lurbinectedin causing fetal abnormalities, the drug is classified as a Category D drug by the FDA, and its effects on fetal development have not been extensively studied. Therefore, it is recommended that pregnant women avoid taking this drug.

Sources:

1. "Lurbinectedin: Mechanism of Action." DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/lurbinectedin>.
2. "Lurbinectedin (Zepzelca): Side Effects, Dosage, Uses, and More." RxList, <https://www.rxlist.com/lurbinectedin-drug.htm>.
3. "FDA Pregnancy Categories." U.S. Food and Drug Administration, <https://www.fda.gov/media/74462/download>.